Bliss Gvs Pharma Limited (BLISSGVS) Stock Statistics & Valuation Metrics

Bliss Gvs Pharma Limited has a market cap or net worth of ₹16.66B. The enterprise value is ₹15.00B.

Bliss Gvs Pharma Limited has 105,445,520 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bliss Gvs Pharma Limited’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 17.22%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Bliss Gvs Pharma Limited had revenue of 8.10B and earned 842.99M in profits. Earnings per share was 8.02.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Bliss Gvs Pharma Limited pays an annual dividend of ₹0.5, resulting in a dividend yield of 0.32%

Bliss Gvs Pharma Limited upcoming earnings date is Jul 25, 2025, TBA (Confirmed).

Bliss Gvs Pharma Limited as a current ratio of 4.81, with Debt / Equity ratio of 8.39%

In the past 12 months, Bliss Gvs Pharma Limited has paid 353.84M in taxes.

Bliss Gvs Pharma Limited EV to EBITDA ratio is 8.99, with an EV/FCF ratio of 38.18.

Bliss Gvs Pharma Limited has ₹2.13B in cash and marketable securities with ₹881.04M in debt, giving a net cash position of -₹1.25B billion.

Gross margin is 40.53%, with operating margin of 35.07%, and net profit margin of 10.41%.

The average price target for Bliss Gvs Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―